From: Benefits, risks, and cost-effectiveness of COVID-19 self-tests from a consumer’s perspective
Input | Mean (range) | Reference |
---|---|---|
Epidemiological and clinical data | ||
IFR in Germany (without vaccine) | 0.014 (0.011–0.017) | |
IFR by age (without vaccine) | Age-specific | |
Percent fully vaccinated | [6] | |
Age 18–59 | 0.72 | |
Age 60+ | 0.84 | |
Vaccine effectiveness against death | [20] | |
Age 18–59 | 0.96 | |
Age 60+ | 0.90 | |
Vaccine effectiveness against ICU admission, age 18+ | 0.93 | [20] |
Lost life years due to COVID-19 | 6.5 | [21] |
Preference weight in the absence of COVID-19 | 0.8 | [22] |
Probability of ICU admission | 0.026 | [19] |
ICU mortality rate | 0.26 | [19] |
Preference weight after ICU discharge | 0.58 | [23] |
Probability of hospital admission, age 80+ | 0.29 | [13] |
Life expectancy after ICU discharge, years | 2.1 | |
Prevalence of long COVID syndrome | 0.025 (0.025–0.117) | [26] |
Preference weight of long COVID syndrome | 0.53 (0.42–0.64) | [27] |
7-day incidence rate | 65 (30–200) | |
Proportion of undetected COVID-19 cases | 0.50 | [16] |
Asymptomatic infection rate | 0.191 | [28] |
Symptomatic infection rate | 0.254 | [28] |
Average incubation period, days | 5.8 | [29] |
Average infectious period, days | 14 | [30] |
Test data | ||
Test sensitivity | 0.81 (0.70–0.90) | [2] |
Test specificity | 0.98 | [2] |
Rapid COVID-19 antigen self-test, € | 2 (0.80–2) | |
Additional data | ||
Annual gross household income, € | 56,808 | [31] |